Skip to main content

Daisy Genomics

Daisy Genomics provides a direct optical long-read sequencing platform that reads native DNA molecules at single-base resolution without amplification, labels, or library preparation. The technology uses surface-enhanced Raman spectroscopy (SERS) and proprietary nanochannels to detect epigenetic modifications and structural variants that other sequencing methods miss, enabling applications in precision medicine, diagnostics, and drug development.

Carlsbad, United States · HQ
Founded 20256700+ followers
  • Biotechnology
  • Healthcare Technology
  • Hardware
  • Artificial Intelligence
Updated 7 days ago

Funding

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current genomic analysis methods often miss critical epigenetic data and important genomic markers, leading to significant diagnostic gaps. Existing next-generation sequencing approaches require DNA amplification and labeling, cannot directly measure epigenetic modifications, and struggle to resolve large structural variants, leaving many disease-relevant genomic regions unseen.

Solution

Daisy Genomics provides a direct optical long-read sequencing platform that sequences native, unamplified nucleic acid molecules at single-base resolution. DNA is loaded onto proprietary nanochannel structures approximately 40nm wide, linearized, and moved past metamaterial/plasmonic enhancement structures where surface-enhanced Raman spectroscopy (SERS) captures a complete spectral fingerprint of each nucleotide, including epigenetic and chemical modifications. This approach requires no amplification, labels, or library preparation and reads sequences in real time, enabling direct assessment of DNA modifications that other technologies cannot detect. The platform supports long-read applications including structural variant detection, haplotype-resolved sequencing, and de novo whole genome assembly, with machine-learning-based data analysis integrated throughout the workflow.

Target Audience

Primary customers are genomics researchers, diagnostics companies, and drug development organizations focused on precision medicine, epigenetic disease mechanisms, and applications requiring long-read sequencing of native DNA.

Features

  • Direct detection of single nucleotides using non-resonant SERS with metamaterial/plasmonic nanostructures, providing direct structural information rather than ionic sensing used by nanopore methods
  • Proprietary nanochannel structures approximately 40nm wide that linearize DNA and integrate enhancement structures with electric-field-controlled velocity
  • No DNA amplification, labeling, or library preparation required; sequences native molecules in real time
  • Direct measurement of epigenetic modifications with distinct spectra, including examples such as dCTP, 5m-dCT, and 5hm-dCTP
  • Ultra-long read capability supporting structural variant detection, haplotype-resolved sequencing, and de novo whole genome assembly
  • Machine-learning-based data analysis integrated into the research and technology platform
This profile is AI-generated and may contain inaccuracies.